4-氨基甲基四氢吡喃-4-羧酸甲酯 | 793658-98-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4-氨基甲基四氢吡喃-4-羧酸甲酯
• 中文别名: 4-氨甲基-四氢吡喃-4-甲酸甲酯
• 英文名称: 4-(aminomethyl)tetrahydropyran-4-carboxylic acid methyl ester
• 英文别名: methyl 4-aminomethyl-tetrahydro-pyran-4-carboxylate；Methyl 4-(aminomethyl)tetrahydro-2H-pyran-4-carboxylate；methyl 4-(aminomethyl)oxane-4-carboxylate
• CAS: 793658-98-7
• 化学式: C₈H₁₅NO₃
• mdl: MFCD07784123
• 分子量: 173.212
• InChiKey: VJTUCQHBOFWNQT-UHFFFAOYSA-N

物化性质

• 沸点：
  248.0±25.0 °C(Predicted)
• 密度：
  1.094±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  4-氨基甲基四氢吡喃-4-羧酸甲酯 在 吡啶 、 4-二甲氨基吡啶 、 sodium methylate 、 三乙酰氧基硼氢化钠 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 水 、 乙腈 为溶剂， 生成
  参考文献：
  名称：

  Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitors

  摘要：

  The identification of a potent, selective, and orally available MK2 inhibitor series is described. The initial absence of oral bioavailability was successfully tackled by moving the basic nitrogen of the spiro-4-piperidyl moiety towards the electron-deficient pyrrolepyridinedione core, thereby reducing the pK(a) and improving Caco-2 permeability. The resulting racemic spiro-3-piperidyl analogues were separated by chiral preparative HPLC, and the activity towards MK2 inhibition was shown to reside mostly in the first eluting stereoisomer. This led to the identification of new MK2 inhibitors, such as (S)-23, with low nanomolar biochemical inhibition (EC(50) 7.4 nM) and submicromolar cellular target engagement activity (EC(50) 0.5 mu M). (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.016
• 作为产物：
  描述：

  4-氰基四氢-2H-吡喃-4-羧酸甲酯 在 platinum(IV) oxide 盐酸 、 氢气 作用下， 以 甲醇 为溶剂， 生成 4-氨基甲基四氢吡喃-4-羧酸甲酯
  参考文献：
  名称：

  Synthesis and structure–activity relationship of a novel, achiral series of TNF-α converting enzyme inhibitors

  摘要：

  A novel series of achiral TNF-alpha converting enzyme (TACE) inhibitors has been discovered. These compounds exhibited activities from 0.35 to 11 nM in a porcine TACE assay and inhibited TNF-alpha production in an LPS-stimulated whole blood assay with an IC50 value of 23 nM for the most potent one. They also have excellent selectivities over related metalloproteases including aggrecanases. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.02.015

文献信息

• [EN] 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS<br/>[FR] COMPOSÉS 4-HYDROXY-ISOQUINOLÉINE COMME INHIBITEURS D'HYDROXYLASE HIF
  申请人：FIBROGEN INC

  公开号：WO2013134660A1

  公开（公告）日：2013-09-12

  The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.

  本发明涉及式(I)的新化合物，以及能够选择性地抑制PHD1酶活性而不影响其他同工酶（例如PHD2和/或PHD3酶）的组合物。该发明还涉及式(I)的化合物在肌肉退化、结肠炎、炎症性肠病和某些缺血症等疾病中的应用。
• [EN] DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA<br/>[FR] INHIBITEURS DE ROR-GAMMA À BASE DE DIHYDROPYRROLOPYRIDINE
  申请人：VITAE PHARMACEUTICALS INC

  公开号：WO2015116904A1

  公开（公告）日：2015-08-06

  Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

  提供了化合物的新结构（I）：其药用盐以及药物组合物，可用于治疗由RORγ介导的疾病和紊乱。还提供了包含化合物的新结构（I）的药物组合物以及其在治疗一个或多个炎症、代谢、自身免疫和其他疾病或紊乱中的使用方法。
• 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS
  申请人：FIBROGEN, INC.

  公开号：US20150038528A1

  公开（公告）日：2015-02-05

  The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.

  本发明涉及公式（I）的新型化合物及其组合物，能够选择性地抑制PHD1酶活性，而不影响其他同工酶，例如PHD2和/或PHD3酶。本发明还涉及公式（I）的化合物在肌肉退化、结肠炎、炎症性肠病和某些缺血症等疾病中的使用。
• DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA
  申请人：VITAE PHARMACEUTICALS, INC.

  公开号：US20150218160A1

  公开（公告）日：2015-08-06

  Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

  提供了式(I)的新化合物：其药学上可接受的盐及其制备的药物组合物，这些化合物对于治疗由RORγ介导的疾病和疾病具有用处。还提供了包含式(I)的新化合物的药物制剂和使用它们治疗一种或多种炎症、代谢、自身免疫和其他疾病或疾病的方法。
• APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：AbbVie Inc.

  公开号：US20150299197A1

  公开（公告）日：2015-10-22

  Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.

  本文公开了一种抑制抗凋亡Bcl-2蛋白活性的化合物，包含这些化合物的组合物以及使用这些化合物治疗疾病的方法。